Arbutus Biopharma Corporation (NASDAQ: ABUS), the biopharmaceutical company known for its focus on developing treatments for chronic Hepatitis B virus (HBV) infection, recently received a noteworthy boost in its stock price target. JMP Securities raised its price objective from $4.00 to $5.00,
The biopharmaceutical and life sciences industry is experiencing dynamic shifts, marked by strategic partnerships, innovative laboratory products, and enhanced service offerings. Companies are increasingly focusing on forming alliances, introducing state-of-the-art equipment, and improving their
Xeris Biopharma Holdings Inc. (NASDAQ: XERS) recently experienced a slight dip in its stock value, closing at $2.48, down -1.59% from the previous day. However, with positive analyst ratings, significant insider buying, and strong institutional support, there are several optimistic indicators for
Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts The global biopharma market is on the cusp of remarkable transformations driven by automation, enabling more efficient production processes and improved product quality. This evolving sector is undergoing significant
The biomanufacturing industry is on the cusp of a transformative era, driven by technological innovations and strategic financial investments. A recent $7.5 million project agreement awarded to Capra Biosciences by the U.S. Department of Health and Human Services’ Administration for Strategic
Pharmaceutical manufacturing is evolving rapidly to keep pace with increasing global demand and stringent regulatory standards. A critical aspect of this evolution is the integration of automation systems to enhance data integrity. Automation ensures compliance with the ALCOA+
